Bellemin Jean-Marc 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Jan 5, 2023
Insider Transaction Report
Form 4
Bellemin Jean-Marc
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-01-03+18,850→ 28,354 total - Exercise/Conversion
Restricted Stock Units
2023-01-03−18,850→ 0 total→ Common stock (18,850 underlying) - Tax Payment
Common Stock
2023-01-03$6.11/sh−10,553$64,479→ 17,801 total
Footnotes (6)
- [F1]This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021.
- [F2]Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
- [F3]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
- [F4]Represents common stock remaining after deducting the common stock withheld for taxes.
- [F5]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F6]As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023.